ML-016 (iNPG-pDox)

About BrYet

BrYet is an early-stage biotechnology company pioneering a physics-based approach to curing metastatic cancer. Its core strategy leverages two proprietary platforms—Transport Oncophysics and Nanoporous Silicon MicroParticles (NSMP)—to design therapeutics that overcome biological barriers and drug resistance. The company's lead candidate, ML-016, has shown unprecedented curative efficacy in preclinical models of lung and liver metastases and has recently entered Phase 1/2 clinical trials following an IND filing.

Therapeutic Areas